FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cholesterol patents



      
           
This page is updated frequently with new Cholesterol-related patent applications. Subscribe to the Cholesterol RSS feed to automatically get the update: related Cholesterol RSS feeds. RSS updates for this page: Cholesterol RSS RSS


Date/App# patent app List of recent Cholesterol-related patents
01/22/15
20150024077
 Composition for treating skin barrier and reducing acne patent thumbnailnew patent Composition for treating skin barrier and reducing acne
A composition for applying to skin suffering from acne to treat the acne, the composition comprising an extract of malva neglecta. The malva neglecta increases ceramide production at the area of skin affected by acne to treat and/or improve the acne.
Johnson & Johnson Consumer Companies Inc.
01/22/15
20150024074
 Methods for treating skin barrier and reducing acne patent thumbnailnew patent Methods for treating skin barrier and reducing acne
A method of treating acne by applying to the skin an extract of malva neglecta topically to the area of skin affected by acne to increase ceramide production at the area of skin affected by acne to treat and/or improve the acne. Additionally, cholesterol may also be applied to the area of skin along with the malva neglecta to treat and/or improve the acne..
Johnson & Johnson Consumer Companies Inc.
01/22/15
20150024009
 Genetically modified organism for the production of lipids patent thumbnailnew patent Genetically modified organism for the production of lipids
The invention provides an isolated genetically modified non-mammalian organism, wherein the activity of acyl-coa:sterol acyltransferase/sterol o-acyltransferase (ec 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol o-acyltranferase (ec 2.3.1.20) and/or lecithin cholesterol acyl transferase/phospholipid: diacylglycerol acyltransferase (ec 2.3.1.158) and/or acyl coa-wax alcohol acyltransferase (ec 2.3.1.75) is reduced or abolished in comparison with a corresponding wildtype organism, methods of use of such an organism, shuttle vehicles for making such an organism and methods for producing such an organism.. .
Organobalance Gmbh
01/15/15
20150019269
 System for rule-based insurance underwriting suitable for use by an automated system patent thumbnailSystem for rule-based insurance underwriting suitable for use by an automated system
A system for at least a partial underwriting of insurance policies is described. Various rules are created, along with a degree of satisfaction for each rule.
Genworth Holdings, Inc.
01/15/15
20150018384
 Treatment for high cholesterol patent thumbnailTreatment for high cholesterol
The present invention provides a method for treatment of high cholesterol by reducing low density lipoprotein cholesterol (ldl-c) and/or very low density opoproiein cholesterol (vldl-c) in subjects in need thereof by administering a compound that inhibits hif hydroxylase activity. The method is useful, for reducing ldl cholesterol levels and total cholesterol levels even in subjects already undergoing treatment with other cholesterol-lowering medications, for example statins, fibrates, nicotinic acids and bile acid-binding resins, and in patients having chronic kidney disease or end stage renal disease, inter alia..
Fibrogen, Inc.
01/15/15
20150017244
 Dry powder formulation of azole derivative for inhalation patent thumbnailDry powder formulation of azole derivative for inhalation
A spray dried-powder composition for inhalation comprising particles (x) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the united states pharmacopoeia at 50 rotation per minute, 37° c. In 900 milliliters of an aqueous dissolution medium adjusted at ph 1.2 and containing 0.3% of sodium laurylsulfate..
Galephar Pharmaceutical Research, Inc.
01/15/15
20150017183
 Single domain antibodies as inhibitors of pcsk9 patent thumbnailSingle domain antibodies as inhibitors of pcsk9
Antibodies (e.g., sdabs) binding to pcsk9 are described. Nucleic acids encoding such abs, host cells expressing such abs and pharmaceutical composition comprising same are described.
National Research Council Canada
01/08/15
20150011595
 Inhibitors of cholesterol ester transfer protein patent thumbnailInhibitors of cholesterol ester transfer protein
The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors..
Concert Pharmaceuticals, Inc.
01/08/15
20150011520
 Pharmaceutical compositions to reduce complications of ocular steroid patent thumbnailPharmaceutical compositions to reduce complications of ocular steroid
The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases..
Tlc Biopharmaceuticals, Inc.
01/08/15
20150010615
 Supercritical guggul extracts and uses thereof patent thumbnailSupercritical guggul extracts and uses thereof
The subject invention pertains to supercritical carbon dioxide extracts of commiphora mukul resin (guggul), which can be modified or not modified by some ethanol addition; methods for their production; and methods of use, such as inhibiting hmg-coa reductase, inhibiting transformation of pre-adipocytes to adipocytes, inhibiting triglyceride storage, promoting insulin sensitivity in adipocytes, treatment of disorders (for example, hypercholesterolemia, hyperlipidemia, hyperglycemia, obesity, metabolic syndrome, cardiovascular disease, atherosclerotic heart disease, autoimmune disorder, insulin resistance, leptin resistance, arthritis, cell proliferation disorder, such as cancer and atherosclerosis; damaged skin, sores, cuts, rashes, bruises, dryness, burns, sunburn, radiation burn, and infection), and regulating or suppressing appetite.. .
Flavex Naturextrakte Gmbh
01/01/15
20150005372

Compositions and methods of altering cholesterol levels


The present invention relates to compositions, methods and kits using polynucleotides, primary transcripts and mmrna molecules.. .
Moderna Therapeutics, Inc.
01/01/15
20150004268

Fat-based food products


The invention is in particular concerned with a food product comprising one or more fats or oils and a carotenoid compound. The products of the invention may be used in reducing elevated total cholesterol, triglycerides and inflammatory damage, as well as improving tissue microcirculation and tissue oxygenation..
Ip Science Limited
01/01/15
20150004218

Compositions and methods for immune tolerance induction


Methods and compositions to reduce immunogenicity of proteins are disclosed. Compositions comprising therapeutic proteins (such as factor viii or any other protein or peptide) complexed with liposomes comprising ps and pc (ps liposomes), or comprising ps, pi and pc and, optionally, cholesterol (ps/pi liposomes) may be used..
The Research Foundation For The State University Of New York
01/01/15
20150004174

Methods for treating homozygous familial hypercholesterolemia


The present invention relates to methods for treating homozygous familial hypercholesterolemia using antibodies against proprotein convertase subtilisin/kexin type 9 (pcsk9).. .
Amgen Inc.
01/01/15
20150004140

Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans


Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kda and 70 kda, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity.
Tate & Lyle Ingredients France Sas
12/25/14
20140378493

Fused bicyclic oxazolidinone cetp inhibitor


Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.. .
Merck Sharp & Dohme Corp.
12/25/14
20140378465

Method of treating diabetes


Methods are provided for treating diabetes, lowering plasma level of hba1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing hdl cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.. .
Gilead Sciences, Inc.
12/25/14
20140377388

Cholesterol discharge-accelerating agent and neutral fat discharge-accelerating agent using sunflower pith


An object of the present invention is to provide a safe and inexpensive substance exhibiting the effects of discharging in vivo cholesterol and neutral fat. The present inventors have discovered that the above object can be achieved using the sunflower stem internal fibers (pith) of plants of the family compositae.
Mottainai Biomass Research Corporation
12/18/14
20140371312

Composition for preventing the occurrence of cardiovascular event in multiple risk patient


Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with hmg-coa ri or a cardiovascular event occurring in a multiple risk patient.. .
Mochida Pharmaceutical Co., Ltd.
12/18/14
20140371303

Compositions and methods for glycemic control of subjects with impaired fasting glucose


Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, hba1c, blood pressure and total cholesterol.. .
Kgk Synergize, Inc.
12/18/14
20140370060

Tear film stability


The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum-producing tissue.. .
Newsouth Innovations Pty Limited
12/18/14
20140370056

Mucosal vaccine using cationic nanogel


A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a mucosal adjuvant. The mucosal vaccine comprises a composite of a nanogel comprising a hydrophilic polysaccharide having a cationic functional group and a hydrophobic cholesterol added thereto as a side chain and a vaccine antigen.
National University Corporation Tokyo Medical And Dental University
12/18/14
20140370047

Products and methods


The invention relates to fungal cells and spores, as well as extracts of either, for use, in particular, in prevention or treatment of chlamydia, or helicobacter pylori or other infections, inflammation, inflammatory, lysosomal, acidic, sod- or igg or other immunoglobulin—peroxidases or hydrogen peroxide induced or other forms of oxidative damage, atherosclerosis, heart disease, stomach, intestinal and liver inflammatory conditions and their complications, promoting or stimulating regeneration or healing of wounds, burns, ulcers, or other forms of damaged or aged tissues, or in reducing elevated cholesterol and/or triglycerides levels in a preferred instance, the fungal cells or spores are those used in the manufacture of fungal fermented cheeses or other food stuff or beverages, particular fungal blue or white cheeses.. .
Ip Science Limited
12/11/14
20140364416

Compositions and methods comprising c16:1n7-palmitoleate


One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising c16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising c16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject..
12/11/14
20140364382

Composition for inhibiting liver function deterioration, containing citrus peel extract or narirutin as active ingredient, and extracting narirutin from citrus peel


The present invention relates to a pharmaceutical composition for treating liver diseases, containing a narirutin extract of citrus peel extract or narirutin as an active ingredient. The extract or narirutin decreases cholesterol levels and fat levels in liver tissue, and thus can be utilized as a composition or food for preventing and treating liver diseases.
12/11/14
20140363845

Cholesterol-based media supplements for cell culture


The disclosure provides compositions and methods for high density cell culture and banking of cholesterol auxotrophic cells.. .
12/11/14
20140363517

Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders


This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain.
12/04/14
20140357854

Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
12/04/14
20140357853

Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
12/04/14
20140357852

Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
12/04/14
20140357851

Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
12/04/14
20140357850

Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
12/04/14
20140357632

Benzopiperazine derivatives as cetp inhibitors


Compounds having the structure of formula ia, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and may be useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.. .
12/04/14
20140356371

Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)


The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more ldl-c subfractions in a patient.
12/04/14
20140356370

Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations


The present invention provides methods for treating autosomal dominant hypercholesterolemia (adh). According to certain embodiments, the adh is caused by or associated with a gain-of-function mutation (gofm) in a gene encoding pcsk9.
11/27/14
20140348997

Beta-cyclodextrin immobilized on glass and cholesterol removal using the same


The present disclosure relates to beta-cyclodextrin immobilized on glass manufactured by method comprising: a) synthesizing mono-6-(p-toluenesulfonyl)-6-deoxy-cyclodextrin from beta-cyclodextrin and converting the mono-6-(p-toluenesulfonyl)-6-deoxy-cyclodextrin into β-cyclodextrin-undecenyl ether; and b) etching borosilicate glass and coating the borosilicate glass with the β-cyclodextrin-undecenyl ether and removal of cholesterol from milk using the same.. .
11/27/14
20140348949

Om vitamin formula


A composition comprising various vitamins to make a multi-vitamin. The vitamins identified in multi-vitamin include vitamin b-1, vitamin b-2, niacinamide, vitamin b-6, vitamin b-12, pantothenic acid, folic acid, beta carotene, iron, biotin, choline, vitamin a, vitamin e and vitamin c.
11/20/14
20140343321

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism


The invention relates to plasminogen activator-1 (pai-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated pai-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated pai-1, cholesterol, or lipid levels..
11/20/14
20140341974

Liposomal vaccine adjuvants and methods of making and using same


A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (dppc), dipalmitoyl phosphatidylglycerol (dppg), dioleoyl phosphatidylcholine (dopc), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.. .
11/13/14
20140336395

Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid


Novel salt forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid characterized by their x-ray powder diffraction pattern and solid-state nmr spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and alzheimer's disease.. .
11/13/14
20140336220

Composition for preventing or treating obesity comprising rebamipide


The present disclosure relates to a composition and a health functional food for preventing or treating obesity comprising a rebamipide compound or its pharmaceutically acceptable salt as an active component. It is confirmed that when a rebamipide compound of the present disclosure is administered to a mouse model induced with obesity, it shows excellent effects of reducing weight, reducing adipocyte, and reducing a total cholesterol content in the body, as compared with a non-administered control group, and also, it shows an excellent effect of suppressing differentiation of cytotoxic th17 cells that generate and secrets inflammatory cytokine and an excellent effect of improving activity of regulatory t cells (treg) capable of suppressing a function of abnormally activated immune cells and controlling an inflammatory reaction.
11/13/14
20140336113

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome


The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
11/13/14
20140335066

Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile


A microorganism strain lactobacillus plantarum inducia dsm 21379 for use as hypocholesterolemic, antimicrobial and anti-oxidative agent and as enhancer of the natural defense potential of a subject. L.
11/06/14
20140328851

Cholesterol ester transfer protein (cetp) inhibitor polypeptide antibodies for prophylactic and therapeutic anti-atherosclerosis treatments


Herein are described two antibodies that can inhibit cetp-lipoproteins interaction and cetp activity. Presently described are an antibody or fragment thereof capable of specifically binding to an epitope of the n-terminal or c-terminal domains of cetp and methods of using these antibodies for separation, identification, diagnosis and therapy..
10/30/14
20140323548

Novel amino alcohol cationic lipids for oligonucleotide delivery


The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that is more efficacious than traditional cationic lipids.
10/30/14
20140322735

Method to measure endogenous enzymatic serum/plasma cholesterol esterification by lcat (lecithin:cholesterol acyltransferase) assay


The present invention provides a method for the assessment of cholesterol esterification through physiologically relevant pathways and incorporates the function of individual subject's endogenous hdl particles. This ex vivo approach avoids the use of an artificial substrate and provides for determination of lcat activity that includes both the contribution of a subject's endogenous hdl function and endogenous lcat protein, and is therefore a significant improvement to the biologic relevance..
10/23/14
20140316124

Modidifed irna agents


The invention relates to irna agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the irna agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety.
10/23/14
20140315928

Substituted amide compounds


The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as ldl-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.. .
10/23/14
20140315873

Animal feed including cationic cholesterol additive and related methods


Methods and feed compositions for increasing health of agricultural animals include administering a cationic cholesterol additive through the diet of the animal, such as through solid feed or drinking water of the animals. The method includes feeding an animal a diet comprised of a cationic cholesterol additive, such as a compound with a sterol backbone and a plurality of cationic groups attached thereto.
10/23/14
20140314844

Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability


The present invention relates to an oral complex formulation comprising omega-3 fatty acid or its derivatives encapsulated in a hard or soft capsule containing sorbitol and sorbitan, as well as an hmg-coa reductase inhibitor. The formulation of the present invention comprising omega-3 fatty acid encapsulated with sorbitol and sorbitan provides better prevention related materials from being formed, leading to improved long-term storage stability.
10/23/14
20140314729

Nutraceutical formulation for treatment of elevated cholesterol and cardiovascular disease


Disclosed are compositions of matter useful for the treatment of elevated blood cholesterol. In one embodiment a nutraceutical composition is administered to a patient in need of said composition comprising of the following combination of ingredients: policosanol, niacin, guggul, garlic, cynara scolymus, red yeast rice, ginger, holy basil, l-carnitine, chromium picolinate, coenzyme q10, pantothenic acid, grape seed extract, momordica charantia, and garcinia indica..
10/16/14
20140309295

Antiepileptic, hypocholesterolemic and neuroprotective compound


Its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. For its use in the prevention of: neurodegenerative diseases, cognitive deterioration, diseases associated with undesired oxidation, age-associated pathological processes and progeria, epilepsy, epileptic seizures and convulsions, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, or fungal or viral infections..
10/16/14
20140308340

Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases


The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhibiting the expression or activity of acyl-coa:cholesterol acyltransferase 1, but not acyl-coa:cholesterol acyltransferase 2.. .
10/16/14
20140308304

Lipids for the delivery of active agents


The present invention relates to novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides, to facilitate the cellular uptake and endosomal escape, and to knockdown target mrna both in vitro and in vivo. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.412

3583

1 - 1 - 71